Iovance Biotherapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Iovance Biotherapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Iovance Biotherapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Iovance Biotherapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
The following section provides information on Iovance Biotherapeutics Inc’s senior management, executives, CEO and key decision makers and their roles in the organization. For more insight into Iovance Biotherapeutics Inc's management and employees, unlock the full data with our company analytics monitoring tool.
Executives
Iain Dukes, Ph.D.
Chairman Executive BoardDr. Iain Dukes has been the Chairman of the company since 2016. Prior to this, he served as the Senior Vice-President and Head of Business Development and Licensing at Merck Research Laboratories. Previously, he served as the Vice President of External Research & Development at Amgen, from 2010 to 2013. He served as the President, Chief Executive Officer, and a member of the Board of Directors at Essentialis Therapeutics from 2007 to 2010.
Frederick G. Vogt, Ph.D.
General Counsel; President; Interim Chief Executive Officer; Director Executive BoardDr. Frederick G. Vogt has been the Interim Chief Executive Officer, President, General Counsel, and Director of the company since 2024. Prior to this, he served as an Associate Patent Attorney at Morgan, Lewis & Bockius LLP. Previously, he served as the Patent Attorney/Manager, Product Development at GlaxoSmithKline.
Corleen Roche
Chief Financial Officer Senior ManagementMs Corleen Roche has been the Chief Financial Officer of the company since August 2025. Prior to this, she served as the Chief Financial Officer at CG Oncology. Previously, she served as the Chief Financial Officer at Chief Financial Officer. She also served as the Chief Financial Officer at CSL Behring, Sandoz, Wyeth and Pfizer.
Igor Bilinsky, Ph.D.
Chief Operating Officer Senior ManagementDr. Igor Bilinsky has been the Chief Operating Officer of the company since 2021. Prior to this, he served as the Chief Business Officer of Oncternal Therapeutics. Previously, he served as the Chief Operating Officer of AmpliPhi Biosciences. Mr. Bilinsky also served as the General Manager and Senior Vice President at IGNYTA.
Friedrich Graf Finckenstein, M.D.
Chief Medical Officer Senior ManagementMr. Friedrich Graf Finckenstein has been the Chief Medical Officer of the company since 2019. Prior to this, he served as the Global Head of Oncology Translational Medicine at Roche Pharma Research and Early Development in Switzerland. Previously, he served as the Medical Group Director at Bristol-Myers Squibb.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer